Biosimilar Insulin and Costs: What Can We Expect?

  title={Biosimilar Insulin and Costs: What Can We Expect?},
  author={Lutz Heinemann},
  journal={Journal of diabetes science and technology},
  volume={10 2},
The costs for insulin treatment are high, and the steady increase in the number of patients with diabetes on insulin presents a true challenge to health care systems. Therefore, all measures to lower these costs are welcomed by patients, physicians, and health care providers. The market introduction of biosimilar insulins presents an option to lower treatment costs as biosimilars are usually offered at a lower price than the originator product. However, the assumption that a drastic reduction… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.